

2026 RESEARCH FAST FACTS

Research Programs Overview



RESEARCH GRANT INVESTMENT AT A GLANCE:

(1982-2026)

Over **\$1.1 billion** in more than **2,800** research grants & more than **600** clinical trials

ABOUT OUR RESEARCH PROGRAMS

Despite successes in awareness and progress in diagnosis and treatment, breast cancer remains a devastating disease. Nearly 43,000 breast cancer deaths are predicted this year in the U.S. alone. “Komen focuses on breakthrough research into aggressive breast cancer types and health disparities to transform future treatment, prevention, and diagnosis. Our focus remains to advance precision medicine, improve health outcomes for everyone, and train the next generation of diverse cancer researchers.

WHAT WE'RE INVESTIGATING



Testing new ways to prevent and treat [invasive lobular cancer](#) (ILC) and finding new biomarkers that can be used to predict ILC recurrence.



Testing the immunotherapy drug avelumab to treat many breast cancers, including hormone receptor-positive, HER2-positive, and triple negative breast cancers.



Developing and testing [new therapies](#), including a novel nanomedicine in TNBC, a new antibody drug conjugate in HER2-positive breast cancer, and new combination therapies to improve outcomes for people with many different types of breast cancer.

IN THE KOMEN RESEARCH PIPELINE (1982-2026):

Nearly **4,300** new breast cancer **research discoveries** (drugs, biomarkers, devices, etc.)

More than **2,400** discoveries to advance **precision medicine** including **1,800** potential **treatments**.



Over **1,800** discoveries focused on **metastatic** and **other deadly and aggressive breast cancers**, with over **1,100** focused on potential treatments.




Over **600** new discoveries focused on strategies to reduce breast cancer **disparities & inequities**.



SPOTLIGHT

Our research investments are guided by more than 50 leading scientists and advocates, including our [Scientific Advisory Board](#), [Komen Scholars](#) and [Advocates in Science](#). As a global leader in the fight against breast cancer, we have funded research in 47 states, DC and Puerto Rico, as well as in 23 different countries. Our commitment to the most promising, innovative, and meaningful breast cancer research will never waver. Read more about Komen's research impact [here](#).



LEARN MORE ABOUT BREAST CANCER

MORE KOMEN-FUNDED RESEARCH STORIES

GET INVOLVED & SUPPORT RESEARCH

WHAT WE'VE LEARNED FROM KOMEN-FUNDED RESEARCH

- A recent clinical trial showed that certain people with metastatic hormone receptor-positive breast cancer can safely reduce their dose of CDK4/6 inhibitor palbociclib, reducing side effects that affect their quality of life. Learn more about treatment dose optimization [here](#).
- A new study found high levels of a protein called CCR7 in [inflammatory breast cancer](#) (IBC), an aggressive breast cancer, making CCR7 a promising target for new antibody-based treatments.
- MAKO (Mammary Analysis for Knowledge of Outcomes), a newly developed artificial intelligence (AI) tool, uses routinely collected tumor specimens to predict recurrence risk in people with early-stage hormone receptor-positive, HER2-negative breast cancers.